Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
STARTREC-3 study - Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer?
Sponsor Radboud universitair medisch centrum Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer (PelvEx II)
Sponsor Catharina Ziekenhuis Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancer
Sponsor BOOG Study Center B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Selecting the optimal position of CDK4/6 inhibitors in HR+ advanced breast cancer: the SONIA trial
Sponsor BOOG Study Center B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study
Sponsor BOOG Study Center B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative breast cancer
Sponsor BOOG Study Center B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting?
The 2026-10-09 snapshot links Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting to 7 distinct CTIS trials. Recorded services include Laboratory services, Clinical monitoring, Data management, Electronic data capture, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting?
The most frequently recorded therapeutic areas are Gastroenterology, Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting conducted?
The linked trials record locations in 9 countries, including Netherlands, Sweden, Belgium, Germany, Spain. These are trial locations, not confirmed office locations or countries where Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting delivered services.
What can this page tell me about Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting